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Since the declaration of war against can-
cer in the National Cancer Act of 1971 by 
then U.S. President Richard Nixon, great 
progress has been made in several areas, 
but it is clear that cancer is a more com-
plex disease than what we had anticipated. 
Despite the high cure rates achieved in some 
hematological malignancies and pediatric 
tumors, progress in the most common 
adult solid tumors has been slower and 
less impressive. However, there are impor-
tant improvements in the understanding of 
the causation of cancer and the molecular 
mechanisms by which cancer develops and 
disseminates, which have allowed a bet-
ter understanding of the biology and the 
definition of new treatment strategies. The 
understanding of these basic mechanisms 
has allowed the development of a number 
of more targeted anticancer agents that are 
exquisitely active in patients whose tumors 
have specific genetic abnormalities.
Prevention and early diagnosis
Overall, an estimated 12.7 million new 
cancer cases and 7.6 million cancer deaths 
occurred in 2008, with 56% of new cancer 
cases and 63% of the cancer deaths occur-
ring in the less developed regions of the 
world, as assessed by the GLOBOCANC, 
which investigated the worldwide inci-
dence and mortality from 27 cancers in 
182 countries in 2008 (Ferlay et al., 2010). 
The most commonly diagnosed cancers 
worldwide are lung (1.61 million, 12.7% of 
the total), breast (1.38 million, 10.9%), and 
colorectal cancers (1.23 million, 9.7%). 
The most common causes of cancer death 
are lung cancer (1.38 million, 18.2% of the 
total), stomach cancer (738,000 deaths, 
9.7%), and liver cancer (696,000 deaths, 
9.2%). Cancer is neither rare anywhere in 
the world, nor mainly confined to high-
resource countries. Striking differences in 
the patterns of cancer from region to region 
are observed. Progress in all these major 
cancer killers has come from prevention, 
screening, and early detection, whereas 
the treatment of cancers in advance stage 
has undergone significant improvements 
but with a much lesser effect on overall 
survival.
Mammography screening every 2 years 
is presently advised in women of 50 years of 
age, up to 75 (US Preventive Services Task 
Force, 2009), although several strongly rec-
ommend to start of age 40.
Screening for cancer of the cervix has 
been in use for years and colonoscopy 
has been more recently advised to prevent 
colorectal cancer. PSA screening for pros-
tate cancer is still highly controversial, but 
used by many. Very recently the results of 
the National Lung Screening trial (NLST) 
have indicated that low dose helical CT scan 
is able to reduce mortality in heavy smok-
ers, compared to chest X-ray. The develop-
ment of imaging techniques or methods to 
assess with precision the risk of develop-
ing tumors is of paramount importance 
in the reduction of the burden of cancer. 
Prevention is of course also very important 
and epidemiological studies have led to the 
adoption of preventing measures that have 
had a major impact in the survival and 
incidence of specific tumor types. As an 
example the banning of cigaret smoke has 
determined the reduction of lung cancer in 
the United States. With the increasing use 
of low dose spiral CT scans for detection 
of early lung cancer we will be seeing an 
increasing number of small nodules and 
lung lesions that will pose challenges to 
the diagnosis and treatment that have so 
far not been faced. The challenge in many 
tumors is the development of more sensi-
tive tests for early diagnosis, using either 
imaging or molecular studies. The ability 
to detect single molecules using very sensi-
tive approaches is probably going to allow 
the use of specific tests in the future.
treatment of early disease
Treatment of solid tumors at a localized 
stage has remained surgery for the most 
part, but we have seen changes in several 
tumor types, to include less mutilating oper-
ations, and organ preserving therapies, e.g., 
in breast cancer, rectal cancer, larynx cancer. 
For example, mastectomy has been replaced 
by smaller resections, to which radiation 
has been added. Chemoradiotherapy has 
become standard in rectal and anal cancer 
and in some forms of head and neck can-
cer, with a significant cure rate, which is 
comparable to that of surgery. In the years 
to come, the use of alternative treatment 
strategies, to limit the extent of surgery, 
together with lesser invasive surgeries, will 
likely make a large impact to how locally 
advanced tumors will be handled.
In several solid tumors adjuvant treat-
ments have become standard, and can 
improve significantly survival, such as in 
breast, colon, and lung cancer. A remarkably 
large number of patients are candidates for 
these treatments and refinements of adju-
vant therapies with increased activity and 
lesser long-time side effects have become 
part of the research programs for these and 
other diseases.
Hereditary cancers
Several forms of cancer have been identi-
fied where a genetic predisposition plays 
an important role in the causation of the 
cancer. BRCA1 and BRCA2 germ line muta-
tions are responsible for 90% of hereditary 
forms of breast and ovarian cancers. Lynch 
syndrome (hereditary non-polyposis colon 
cancer, HNPCC) is caused by mutations in 
one of six genes involved in DNA mispatch 
repair, and is responsible for about 2–3% 
of colon cancer cases. Another 1% of colon 
cancers is caused by mutations in the APC 
gene, which is associated with familial 
adenomatous polyposis. Retinoblastoma 
is hereditary and due to mutations in the 
Rb gene in about 40% of cases of retino-
blastomas. Mutations in several other genes 
also predispose to a variety of cancers. For 
example LKB1 mutations associated with 
Peutz–Jeghers syndrome predispose to 
gastric cancer as well as other cancer. The 
Lee–Fraumeni syndrome, caused by p53 
mutations, also predisposes patients to a 
variety of tumor types.
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novel  bioinformatics tools and strategies 
to store and analyze the information need 
to be developed. Technology has drastically 
reduced the amount of time and money 
needed to study cancer at genome-wide 
level, but challenges remain in the devel-
opment of tools to analyze data in a timely 
fashion and in storing of large information 
datasets. The discovery of novel targets for 
treatment, prognostic factors and potentially 
genetic predisposition factors are being pur-
sued by large sequencing projects in several 
tumor types. Large initiatives are bringing to 
light the discovery of genetic abnormalities 
in the most common tumor types.
new PersPectives
Certainly there is a lot of fervor in the defini-
tion of cancer genetics and this will prob-
ably lead to more discoveries of treatments 
that may be specifically target vulnerable 
functions within the cancer cell. However, 
systemic treatment of advanced disease is 
unlikely to produce major improvement in 
survival of the most common cancer types, 
since these common solid tumors usually 
have redundant mutations that make the 
tumor heterogeneous and very plastic and 
dynamic, with development of drug resist-
ance mechanisms in a very quick fashion. 
Although important discoveries have been 
made with targeted therapies, they really 
substantially affect only a minority of 
the cancer types (e.g., CML, GIST, BRAF 
mutant melanoma, EGFR mutant lung 
cancer, ALK positive lung cancer, etc.). 
Although it is possible that more activating 
mutations and targetable genetic defects be 
discovered, most solid tumors are hetero-
geneous and therefore escape mutants will 
likely be present from start, and/or emerge 
quickly following drug pressure.
Thus, major improvements in overall 
survival will likely continue to rely heav-
ily upon early detection and prevention 
strategies.
frontiers in oncology
This new open access journal has one of the 
major goals to be the forum for publica-
tions in the most important areas of cancer 
research, spanning from diagnosis, and pre-
vention to treatment of early and advanced 
cancer and drug development, to the most 
cutting edge technologies that can be imple-
mented to study cancer and improve its 
treatment. The fast pace of research and its 
Important improvements have also 
recently been seen with the use of immu-
nological approaches. Important examples 
are provenge for castrate-resistant prostate 
cancer (Plosker, 2011) and ipilimumab for 
advanced melanoma (Robert et al., 2011). 
Vaccines and other immunotherapies are 
presently being investigated in other solid 
tumors.
The way forward appears however to 
be in combinations of different drugs and 
approaches, in the attempt to utilize differ-
ent mechanisms of action that tackle one 
or more cancer pathways, and to overcome 
the several potential mechanisms of resist-
ance. The challenge is represented by over-
lapping toxicities of the different drugs. 
Patient selection for particular combina-
tions remains a challenge and improve-
ment is needed in this regard. Preclinical 
testing of combinations will need to be 
perfected, since the current methods for 
in vitro and in vivo testing of combinations 
are poorly predictive of additive or syner-
gistic interactions.
advances in basic science
There has been tremendous progress in the 
understanding of the cancer process, trans-
formation, progression, and metastasis. 
This has led to better strategies to approach 
a number of cancers and potentially novel 
therapeutics. The theory of the cancer stem 
cell has paved the way to the development 
of novel strategies aimed at the eradication 
of cell clones that are essentially resistant 
to standard therapies and that potentially 
have markers that can be targeted specifi-
cally (e.g., Wnt, Notch, hedge hog path-
ways among others; Clevers, 2011). Drug 
development is in progress in the attempt 
to target specific cancer stem cell molecules. 
Clinical trials of cancer stem cell targeted 
agents may require different patient popu-
lations or endpoints as compared to those 
testing conventional drugs, since only a 
small population of cells will be targeted 
by these agents, which might be best suited 
after cytoreductive treatments such as sur-
gery or induction chemotherapy have been 
applied.
With the pace of whole genome sequenc-
ing, functional genomics, and proteom-
ics applied to the cancer, we are presently 
facing an enormous amount of data that 
is being generated (Parsons et al., 2008). In 
order to make sense of this mass of data, 
More recently low penetrance SNPs 
have also been implicated in determining a 
higher risk of cancer, as identified by GWAS 
studies (Freedman et al., 2011).
Counseling and specific follow up and 
treatment strategies for patients affected by 
genetic predisposition to cancer and their 
families, have been developed and have 
become an important part of comprehen-
sive cancer care.
virus induced cancer and 
Prevention
Since the introduction of the theories of 
cancer inducing viruses (cancer virus or 
oncovirus), hepatitis viruses, EBV, HPV, and 
many other viruses have been unequivo-
cally identified as initiators of carcinogen-
esis. Prevention strategies and vaccination 
strategies have been developed for several 
of these diseases. The development of an 
HPV vaccine for cervical cancer has been a 
major breakthrough that has led to vaccina-
tion programs in high risk women, and may 
have broader implications in other HPV 
mediated cancers, such as head and neck 
HPV induced carcinomas. Analogously, 
prevention of hepatitis induced liver cancer 
has broad impact in the development of the 
disease in geographic areas where hepatitis 
virus infection is endemic, such as in large 
areas of Asia and Africa.
treatment of advanced disease
Despite the success obtained in hemato-
logical malignancies, and that obtained in 
testicular cancer, which can be cured with 
chemotherapy in the vast majority of cases 
even at advanced stage, most solid tumors 
have not witnessed such improvement in 
cure rates or survival. The introduction of 
targeted therapies for specifically defined 
subsets of patients has made a major impact 
in the treatment of diseases where standard 
therapies had poor impact, such as CML and 
GIST with imatinib, EGFR tyrosine kinase 
inhibitors for EGFR mutant non-small cell 
lung cancer, ALK inhibitors for non-small 
cell lung cancers with ALK translocations, 
BRAF inhibitors for BRAF mutant mela-
noma, Her2 inhibitors for Her2 amplified 
breast cancer, to cite a few examples. Other 
targeted agents have however been success-
fully developed, which target the microen-
vironment and angiogenesis rather than the 
cancer cells, and where patient selection has 
been challenging.
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ever increasing scope and breath, require a 
comprehensive forum that allows both the 
depth of research and a broad readership. 
This will be accomplished by a large series of 
subspecialties within Frontiers in Oncology, 
which span the major areas of disease-ori-
ented research, epidemiology and preven-
tion, treatment, and basic research.
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